Akebia succeeds in European patent dispute a 2nd time
A Cloud Migration Plan for Corporations featuring Snowflake®
Investor Activism Campaigns Hit Record High in 2022
Essential IR Insights Newsletter - February 2023
Insight Weekly: US bank margins rise; smartphone shipments drop; coal miners book strong sales
The European Patent Office's Opposition Division revoked another of FibroGen Inc.'s patents related to hypoxia-inducible factor, or HIF, for the treatment of kidney disease.
This is the second of FibroGen's patents related to HIF that was revoked due to a challenge from Akebia Therapeutics Inc.
